Rhoda Arzoomanian
- Oncology top 10%
- Cancer Treatment and Pharmacology 12
- Colorectal Cancer Treatments and Studies 4
- Cancer Research top 10%
- Pathology and Forensic Medicine top 10%
-
- Cancer therapeutics and mechanisms 4
-
- Glioma Diagnosis and Treatment 2
-
- Prostate Cancer Treatment and Research 3
- Lung Cancer Treatments and Mutations 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 2
-
- Pharmacogenetics and Drug Metabolism 2
- Co-authors
- Dona AlbertiGeorge WildingKendra D. TutschRebecca MarnochaHoward H. BaileyChris FeierabendAmy DresenKim Binger
- Partner nations
- United StatesSpainGermany
In The Last Decade
Rhoda Arzoomanian
27 papers receiving 910 citations
Peers
Comparison fields: 5 of 91
- Oncology 319
- Cancer Research 160
- Pathology and Forensic Medicine 139
- Molecular Biology 510
- Genetics 66
Countries citing papers authored by Rhoda Arzoomanian
This map shows the geographic impact of Rhoda Arzoomanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhoda Arzoomanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhoda Arzoomanian more than expected).
Fields of papers citing papers by Rhoda Arzoomanian
This network shows the impact of papers produced by Rhoda Arzoomanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhoda Arzoomanian. The network helps show where Rhoda Arzoomanian may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rhoda Arzoomanian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 2 | |
| 2 | 2004 | 11 | |
| 3 | 2004 | 17 | |
| 4 | 2003 | 45 | |
| 5 | 2003 | 3 | |
| 6 | 2003 | 2 | |
| 7 | Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. | 2003 | 63 |
| 8 | 2002 | 100 | |
| 9 | 2002 | 2 | |
| 10 | Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. | 2002 | 57 |
| 11 | Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. | 2002 | 16 |
| 12 | 2001 | 16 | |
| 13 | 1999 | 23 | |
| 14 | 1999 | 5 | |
| 15 | 1998 | 33 | |
| 16 | 1997 | 5 | |
| 17 | 1995 | 2 | |
| 18 | 1993 | 7 | |
| 19 | 1992 | 2 | |
| 20 | 1992 | 18 |
About Rhoda Arzoomanian
Rhoda Arzoomanian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology, having authored 27 papers that have together received 947 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer therapeutics and mechanisms (4 papers), Prostate Cancer Treatment and Research (3 papers), Lung Cancer Treatments and Mutations (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Glioma Diagnosis and Treatment (2 papers) and Pharmacogenetics and Drug Metabolism (2 papers). The work is most often cited by research in Oncology (319 citations), Cancer Research (160 citations) and Pathology and Forensic Medicine (139 citations). Rhoda Arzoomanian has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Dona Alberti, George Wilding, Kendra D. Tutsch, Rebecca Marnocha, Howard H. Bailey, Chris Feierabend, Amy Dresen, Kim Binger, James P. Thomas and Gregory H. Ripple. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.